Healthcare - Biotechnology - NASDAQ - US
$ 25.05
-12 %
$ 3.61 B
Market Cap
-9.08
P/E
INCOME STATEMENT
331 M
REVENUE
-197 M
OPERATING INCOME
-145 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Denali Therapeutics Inc.
| Revenue | 331 M |
| Cost Of Revenue | 424 M |
| Gross Profit | -93.3 M |
| Operating Expenses | 527 M |
| Operating Income | -197 M |
| Other Expenses | -51.5 M |
| Net Income | -145 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 330.5 | 108.5 | 48.7 | 335.7 | 26.7 | 129.2 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 423.9 | 7.0 | 5.6 | 212.6 | 193.4 | 7.4 | 3.1 | 1.5 | 0.1 |
| Gross Profit | (93.3) | 101.4 | 43.1 | 123.0 | (166.7) | 121.7 | (3.1) | (1.5) | (0.1) |
| OPERATING INCOME | |||||||||
| Operating Expenses | 527.2 | 449.2 | 344.4 | 272.9 | 239.9 | 175.5 | 90.1 | 87.4 | 16.7 |
| Selling, General and Administrative Expenses | 103.4 | 90.5 | 79.1 | 60.3 | 46.5 | 32.3 | 15.7 | 11.7 | 5.1 |
| Research and Development Expenses | 423.9 | 358.7 | 265.4 | 212.6 | 193.4 | 143.2 | 74.5 | 75.7 | 11.6 |
| Operating Income | (196.7) | (340.7) | (295.8) | 62.7 | (213.2) | (46.4) | (90.1) | (87.4) | (16.7) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 0 | 14.8 | 0 | 0 | 15.2 | 0 | 2.0 | 0 | 0 |
| Total Other Income | 51.5 | 14.8 | 4.6 | 9.2 | 15.2 | 10.1 | 2.0 | 0.8 | (0.1) |
| Pre-Tax Income | (145.2) | (326.0) | (291.2) | 72.0 | (198.0) | (36.2) | (88.2) | (86.7) | (16.8) |
| NET INCOME | |||||||||
| Tax Provision | 30 K | 21 K | (0.6) | 0.8 | (0.4) | 10.1 | (3.1) | 0 | 0 |
| Net Income | (145.2) | (326.0) | (290.6) | 71.1 | (197.6) | (36.2) | (88.2) | (86.7) | (16.8) |
| EPS | 1.06 | 2.6 | 2.39 | 0.65 | 2.07 | 0.39 | 5.89 | 13.5 | 5.58 |